Bayer (DB:BAYA) - Stock Price, News & Analysis

BAYA Stock Overview

Operates as a life science company worldwide. More details

BAYA fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 85.3% below our estimate of its fair value

Earnings are forecast to grow 55.74% per year

Earnings have grown 25.6% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Debt is not well covered by operating cash flow

Volatile share price over the past 3 months compared to the German market

Bayer Aktiengesellschaft Competitors

Merck KGaA

XTRA:MRK

€60.1b

Dermapharm Holding

XTRA:DMP

€2.0b

PharmaSGP Holding

XTRA:PSG

€283.0m

Sartorius

XTRA:SRT3

€12.8b

Price History & Performance

Summary of all time highs, changes and price drops for Bayer
Historical stock prices
Current Share Price	€4.70
52 Week High	€9.10
52 Week Low	€4.68
Beta	1
11 Month Change	-28.79%
3 Month Change	-30.88%
1 Year Change	-41.25%
33 Year Change	-59.83%
5 Year Change	-72.51%
Change since IPO	-67.59%

Recent updates

Shareholder Returns

	BAYA	DE Pharmaceuticals	DE Market
7D	-10.5%	-7.0%	-0.4%
1Y	-41.3%	-21.6%	7.1%

Return vs Industry: BAYA underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.

Return vs Market: BAYA underperformed the German Market which returned 7.1% over the past year.

Price Volatility

Is BAYA's price volatile compared to industry and market?
BAYA volatility
BAYA Average Weekly Movement	9.0%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: BAYA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: BAYA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1863	94,245	Bill Anderson	www.bayer.com

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.

Bayer Aktiengesellschaft Fundamentals Summary

How do Bayer's earnings and revenue compare to its market cap?
BAYA fundamental statistics
Market cap	€19.17b
Earnings (TTM)	-€880.00m
Revenue (TTM)	€46.74b

0.4x

P/S Ratio

-21.8x

P/E Ratio

Is BAYA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BAYA income statement (TTM)
Revenue	€46.74b
Cost of Revenue	€20.03b
Gross Profit	€26.71b
Other Expenses	€27.59b
Earnings	-€880.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 05, 2025

Earnings per share (EPS)	-0.90
Gross Margin	57.15%
Net Profit Margin	-1.88%
Debt/Equity Ratio	134.1%

How did BAYA perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

-12%

Payout Ratio

BAYA Stock Overview

Rewards

Risk Analysis

Bayer Aktiengesellschaft Competitors

XTRA:MRK

€60.1b

XTRA:DMP

€2.0b

XTRA:PSG

€283.0m

XTRA:SRT3

€12.8b

Price History & Performance

Recent News & Updates

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Recent updates

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

Bayer Aktiengesellschaft (XTRA:BAYN) completed the acquisition of Blackford Analysis Ltd.

Bayer AG Announces CEO Changes

Inclusive Capital Partners Provides Information to Shareholders of Bayer Aktiengesellschaft

Union Investment Criticizes Bayer AG Chairman for Lack of Engagement

Bayer Aktiengesellschaft (XTRA:BAYN) agreed to acquire Blackford Analysis Ltd.

Bayer Aktiengesellschaft to Report Q2, 2023 Results on Aug 08, 2023

Afrin WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays

Bayer Aktiengesellschaft (XTRA:BAYN) acquired Targenomix GmbH.

Bayer Aktiengesellschaft Extends Development Program for Investigational Product Elinzanetant with Phase III Study in Breast Cancer Patients with Vasomotor Symptoms Caused by Endocrine Therapy

Bayer to Highlight Additional Analyses From Comprehensive KERENDIA® (finerenone) Clinical Trial Program at the American Society of Nephrology’s 2022 Kidney Week

Cinven Limited completed the acquisition of Environmental Science Professional business from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Demonstrates Commitment to Advancing Oncology by Showcasing New Data from Innovative Science At ESMO Congress 2022

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

Bayer to Present Data From Cardiovascular Portfolio, Including a Late-Breaking Presentation From FIDELITY for KERENDIA® (finerenone) and New Phase IIb Data From PACIFIC Trial Program for the Oral Factor XIa Inhibitor asundexian

Bayer Launches ForGround

U.S. FDA Approves Bayer's Additional Indication of NUBEQA (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Bayer Aktiengesellschaft (XTRA:BAYN) signed a shareholders agreement to acquire 65% stake in CoverCress Inc. from Bunge Ventures and Chevron U.S.A. Inc.

Keensight Capital alongside management of Axxam entered into an agreement to acquire Axxam SpA from Bayer Aktiengesellschaft (XTRA:BAYN) and Zambon Company S.p.A.

Bayer Announces Prescription-Strength Astepro® Allergy

Shareholder Returns